Compare IDEXX Laboratories, Inc. (IDXX) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs NetEase Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while NetEase Inc trades at $124.27 (market cap $76.09B). The key difference: NetEase Inc is the larger of the two by market cap, and NetEase Inc pays a 2.45% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and NetEase Inc for 73 Days on average.
| IDXX | NTES | |
|---|---|---|
Market Cap | $40.43B | $76.09B |
Volume | 692,164 | 486,447 |
Sector | Health | Technology |
52-Week High | $766.68 | $152.85 |
52-Week Low | $504.70 | $109.26 |
Typical Hold Time | 46 Days | 73 Days |
Enterprise Value | $41.32B | $51.81B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
NTES trades at $124.24, up 3.01% today, with a neutral technical signal and bearish moving averages. The stock shows strong fundamentals with a P/E of 15.92, net income margin of 27.88%, and robust cash flow from operations of $50.74 billion in 2025. Recent earnings were mixed, with a Q2 2026 miss but a Q1 2026 beat. Analyst consensus is strongly bullish with an $168 price target. News highlights focus on earnings results and long-term dividend growth potential.
The outlook for NTES is positive, supported by strong profitability, a healthy balance sheet, and analyst optimism. Key opportunities include revenue growth and AI investments, while risks involve earnings volatility and competitive pressures in the gaming sector. The stock presents a compelling case for growth investors seeking exposure to China's tech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
